Brief: Pyxis Oncology Announces Dosing Of First Subject In Phase 1 Trial Of Pyx-201, A Novel ADC For Solid Tumors
16/03/2023 11:43
March 16 (Reuters) - Pyxis Oncology Inc PYXS.O :
* PYXIS ONCOLOGY ANNOUNCES DOSING OF FIRST SUBJECT IN PHASE
1
TRIAL OF PYX-201, A NOVEL ADC FOR SOLID TUMORS
* PYXIS ONCOLOGY INC - PRELIMINARY DATA ANTICIPATED IN EARLY
2024
Source text for Eikon: ID:nGNX871ZrG
Further company coverage: PYXS.O
((Reuters.Briefs@thomsonreuters.com;))